全球心臟病学和神经病学 IVD 市场

预计到 2030 年，全球心臟病学和神经病学 IVD 市场规模将达到 278 亿美元

2024年，全球心臟病学和神经病学体外诊断器材市场规模估计为173亿美元，预计到2030年将达到278亿美元，2024年至2030年的复合年增长率为8.2%。本报告分析的细分市场之一－仪器市场，预期复合年增长率为9.8%，到分析期结束时规模将达到170亿美元。试剂和耗材市场在分析期间的复合年增长率估计为5.8%。

美国市场规模估计为 47 亿美元，中国市场预计复合年增长率为 13.1%

美国心臟病学和神经病学体外诊断 (IVD) 市场规模预计在 2024 年达到 47 亿美元。作为世界第二大经济体，中国预计到 2030 年市场规模将达到 61 亿美元，在 2024-2030 年的分析期内，复合年增长率为 13.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为 4.0% 和 8.0%。在欧洲，预计德国的复合年增长率为 5.5%。

心臟病学和神经病学的体外诊断市场—关键趋势和驱动因素摘要

心臟病学和神经病学领域的体外诊断 (IVD) 技术正在快速发展，帮助实现早期疾病检测、风险评估和个人化治疗策略。心血管疾病和神经系统疾病是全球死亡和残疾的主要原因，IVD 技术在改善患者预后方面发挥关键作用。基于生物标记的检测、分子诊断、照护现场(POC) 和数位健康整合的进步正在推动该领域的创新。

随着心臟病、中风、神经退化性疾病和认知障碍的发病率不断上升，医疗保健提供者和研究人员越来越依赖体外诊断 (IVD) 解决方案来实现精准诊断、疾病监测和治疗优化。对高灵敏度心臟和神经系统生物标记、人工智慧主导的诊断和快速检测解决方案的需求正在推动市场成长并改变临床决策。

科技进步如何增强心臟科的体外诊断？

心臟体外诊断领域取得了突破性进展，尤其是在高灵敏度检测、照护现场心臟生物标记检测和分子诊断方面。其中最重要的创新之一是高灵敏度心肌肌钙蛋白 (hs-cTn) 检测的开发，该检测能够早期发现心肌梗塞 (MI) 和急性冠状动脉症候群(ACS)。这些超灵敏的检测能够检测到心肌肌钙蛋白水平的细微变化，从而实现早期疗育，改善风险分层，并减少住院治疗。

另一项重大进展是整合多种生物标记组合，用于心血管疾病风险评估。传统上，血脂谱（低密度脂蛋白 (LDL)、高密度脂蛋白 (HDL)、总胆固醇、三酸甘油酯）一直是评估心血管健康状况的标准。然而，现代体外诊断 (IVD) 解决方案融合了高敏感性 C 反应蛋白 (hs-CRP)、利钠肽 (BNP/NT-proBNP) 和髓过氧化物酶 (MPO) 等生物标记物，从而提供全面的心血管风险洞察。这些先进的生物标记测量方法能够制定个人化的预防策略，并实现早期心血管疾病 (CVD) 介入。

另一个重要趋势是心臟标记照护现场检测 (POC) 的扩展。如今，可携式、快速、手持式 POC 分析仪可在急诊室、救护车和初级保健机构即时检测肌钙蛋白、D-二聚体和脑钠肽 (BNP)。这显着改善了早期分流决策，缩短了周转时间，并增强了院前心臟事件管理。此外，穿戴式生物感测器和远端心臟监测设备的兴起使得持续的心臟健康追踪成为可能，从而促进了主动干预，并减少了因心臟衰竭和心律不整而住院的人数。

此外，遗传性心血管疾病的分子和基因检测正在改变疾病的预防和管理。遗传性高胆固醇症(FH)、肥厚型心肌病(HCM) 和长QT症候群 (LQTS) 等疾病的基因筛检正变得越来越普及，这使得早期识别高危险群并针对性地制定生活方式和药物干预措施成为可能。基于人工智慧的心电图解读与数位病理学的融合也正在推动心血管疾病 (CVD) 的自动化诊断和预后。

推动神经病学 IVD 发展的市场趋势是什么？

受神经退化性疾病、中风和认知障碍日益加重的负担所推动，神经诊断领域正在经历快速变化。其中最重要的趋势之一是开发阿兹海默症(AD) 和帕金森氏症 (PD) 的血液生物标记。传统上， 阿兹海默症 的诊断依赖脑脊髓液 (CSF) 分析或 PET 影像，这两种方法都具有侵入性且昂贵。然而，近年来，基于血浆的 β-淀粉样蛋白（Aβ42/Aβ40 比率）、 Tau蛋白（pTau-181、pTau-217）和神经丝轻链 (NfL) 检测方法的进展，使得对阿兹海默症和其他神经退化性疾病进行非侵入性且可扩展的筛检成为可能。

另一个主要趋势是神经病学中分子诊断技术的扩展，特别是针对神经发育障碍、癫痫和神经肌肉疾病的基因检测。次世代定序仪(NGS) 和 CRISPR 技术在诊断方法上的进步，使得早期发现与肌萎缩侧索硬化症 (ALS)、多发性硬化症 (MS) 和遗传性共济失调等疾病相关的基因突变成为可能。这些精准的诊断工具有助于个人化治疗选择、早期疗育和标靶基因治疗。

用于卒中诊断和管理的体外诊断 (IVD) 解决方案的兴起也推动了市场的成长。传统上，卒中诊断依赖神经影像学（CT、MRI），但神经胶质纤维酸性蛋白 (GFAP)、S100B 和 D-二聚体等卒中生物标记组合的引入，增强了卒中的早期发现以及缺血性卒中和出血性卒中的鑑别诊断。即时血液中风检测 (POC) 正成为院前中风评估的颠覆性技术，能够加快介入速度并改善患者预后。

此外，人工智慧神经诊断、数位生物标记和远端监控的日益融合正在改变神经系统疾病的检测和进展追踪：人工智慧对脑电图、核磁共振成像和语音模式的分析正在改善癫痫、失智症和运动障碍的诊断，而可穿戴神经技术则可以对帕金森氏症、多发性硬化症和中风后復健进行即时神经监测。

什么因素推动了心臟病学和神经病学 IVD 的发展？

循环系统和神经系统体外诊断 (IVD) 市场正在不断扩张，这得益于几个关键的增长驱动因素，包括心血管和神经退化性疾病患病率的上升、生物标誌物发现的进步以及对非侵入性诊断的需求不断增长。最重要的成长要素之一是全球心血管疾病 (CVD) 和中风的负担，它们仍然是全球主要死亡原因。随着医疗保健系统专注于早期检测、预防和个人化治疗方法，对灵敏的心臟生物标记和快速中风诊断的需求正在加速成长。

另一个关键驱动因素是人口老化，这导致阿兹海默症和帕金森氏症等神经退化性疾病的发生率不断上升。随着早期发现和介入成为优先事项，基于血液生物标记、基因筛检和人工智慧神经影像的体外诊断 (IVD) 解决方案正在蓬勃发展。

市场成长也得益于照护现场(POC) 检测和分散式诊断的日益普及。从医院实验室检测到可携式快速诊断解决方案的转变，使得决策速度更快、患者分诊更精准，并能更好地管理急性心臟疾病和神经系统疾病。随着急诊、初级保健和家庭诊断的普及，IVD 製造商正在投资紧凑、易用且高灵敏度的即时诊断 (POC) 检测平台。

体外诊断（IVD）主导的精准医疗的监管和报销支持也是影响市场成长的关键因素。各国政府和医疗机构正在推广生物标记主导的治疗策略、遗传性疾病的基因检测以及人工智慧整合诊断，以优化患者治疗效果并降低医疗成本。此外，对数位医疗技术和远端患者监护的投资不断增加，也推动了人工智慧辅助心臟和神经系统诊断的创新。

部分

产品类型（仪器、试剂和耗材、软体和服务）、技术（免疫检测测定、分子诊断、血液学、其他）、最终用户（医院、临床实验室、其他）

受访公司范例

• Abbott Laboratories
• Agilent Technologies
• AliveCor
• Becton, Dickinson and Company（BD）
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• DiaSorin SpA
• Hologic Inc.
• LivaNova
• Medtronic
• Mindray Medical International Limited
• Ortho Clinical Diagnostics
• PerkinElmer Inc.
• QIAGEN NV
• Roche Diagnostics
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global Industry Analysts 没有查询通用的 LLM 或特定产业的SLM，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地以及进出口情况（成品和原始OEM）预测其竞争地位的变化。这种复杂多变的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global IVD in Cardiology and Neurology Market to Reach US$27.8 Billion by 2030

The global market for IVD in Cardiology and Neurology estimated at US$17.3 Billion in the year 2024, is expected to reach US$27.8 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$17.0 Billion by the end of the analysis period. Growth in the Reagents & Consumables segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.7 Billion While China is Forecast to Grow at 13.1% CAGR

The IVD in Cardiology and Neurology market in the U.S. is estimated at US$4.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.1 Billion by the year 2030 trailing a CAGR of 13.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

IVD in Cardiology and Neurology Market - Key Trends & Drivers Summarized

In-vitro diagnostics (IVD) in cardiology and neurology is rapidly evolving, enabling early disease detection, risk assessment, and personalized treatment strategies. As cardiovascular and neurological disorders continue to be leading causes of mortality and disability worldwide, IVD technologies are playing a crucial role in improving patient outcomes. Advances in biomarker-based testing, molecular diagnostics, point-of-care (POC) testing, and digital health integration are driving innovation in this sector.

With the rising prevalence of heart disease, stroke, neurodegenerative disorders, and cognitive impairments, healthcare providers and researchers are increasingly relying on IVD solutions for accurate diagnosis, disease monitoring, and therapy optimization. The demand for high-sensitivity cardiac and neurological biomarkers, AI-driven diagnostics, and rapid testing solutions is fueling market growth and transforming clinical decision-making.

How Are Technological Advancements Enhancing IVD in Cardiology?

The field of cardiac in-vitro diagnostics has witnessed groundbreaking advancements, particularly in high-sensitivity assays, point-of-care cardiac biomarker testing, and molecular diagnostics. One of the most significant innovations is the development of high-sensitivity cardiac troponin (hs-cTn) tests, which enable the early detection of myocardial infarction (MI) and acute coronary syndrome (ACS). These ultrasensitive assays detect minute changes in cardiac troponin levels, allowing for earlier intervention, improved risk stratification, and reduced hospital admissions.

Another major breakthrough is the integration of multi-biomarker panels for cardiovascular disease risk assessment. Traditionally, lipid profiles (LDL, HDL, total cholesterol, and triglycerides) were the standard for evaluating cardiovascular health. However, modern IVD solutions now incorporate additional biomarkers such as high-sensitivity C-reactive protein (hs-CRP), natriuretic peptides (BNP/NT-proBNP), and myeloperoxidase (MPO) to provide comprehensive cardiovascular risk insights. These advanced biomarker assays are enabling personalized preventive strategies and early-stage cardiovascular disease (CVD) intervention.

The expansion of point-of-care (POC) testing for cardiac markers is another critical trend. Portable, rapid, and handheld POC analyzers now allow for real-time troponin, D-dimer, and BNP testing in emergency rooms, ambulances, and primary care settings. This has significantly improved early triage decisions, reduced turnaround times, and enhanced pre-hospital cardiac event management. Additionally, the rise of wearable biosensors and remote cardiac monitoring devices is enabling continuous cardiac health tracking, leading to proactive interventions and reduced hospitalizations for heart failure and arrhythmias.

Furthermore, molecular and genetic testing for inherited cardiovascular conditions is transforming disease prevention and management. Genetic screening for conditions such as familial hypercholesterolemia (FH), hypertrophic cardiomyopathy (HCM), and long QT syndrome (LQTS) is becoming more accessible, allowing early identification of at-risk individuals and targeted lifestyle or pharmacological interventions. The integration of AI-driven ECG interpretation and digital pathology is also advancing automated CVD diagnosis and prognosis prediction.

What Market Trends Are Driving IVD in Neurology?

The field of neurological diagnostics is undergoing rapid transformation, fueled by the increasing burden of neurodegenerative diseases, stroke, and cognitive disorders. One of the most significant trends is the development of blood-based biomarkers for Alzheimer’s disease (AD) and Parkinson’s disease (PD). Traditionally, the diagnosis of Alzheimer’s relied on cerebrospinal fluid (CSF) analysis or PET imaging, both of which are invasive and expensive. However, recent advancements in plasma-based assays for beta-amyloid (Aβ42/Aβ40 ratio), tau proteins (pTau-181, pTau-217), and neurofilament light chain (NfL) have enabled non-invasive and scalable screening for Alzheimer’s and other neurodegenerative diseases.

Another major trend is the expansion of molecular diagnostics in neurology, particularly in genetic testing for neurodevelopmental disorders, epilepsy, and neuromuscular conditions. Advances in next-generation sequencing (NGS) and CRISPR-based diagnostics are enabling early detection of genetic mutations linked to conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and hereditary ataxias. These precision diagnostic tools are facilitating personalized treatment selection, early interventions, and targeted gene therapies.

The rise of IVD solutions for stroke diagnosis and management is also driving market growth. Traditionally, stroke diagnosis relied on neuroimaging (CT, MRI); however, the introduction of stroke biomarker panels, including glial fibrillary acidic protein (GFAP), S100B, and D-dimer, is enhancing early stroke detection and differentiation between ischemic and hemorrhagic strokes. POC blood-based stroke tests are emerging as a game-changer for pre-hospital stroke assessment, allowing for rapid intervention and better patient outcomes.

Additionally, the growing integration of AI-driven neurodiagnostics, digital biomarkers, and remote monitoring is transforming neurological disease detection and progression tracking. AI-powered analysis of EEG, MRI, and speech patterns is improving the diagnosis of epilepsy, dementia, and movement disorders, while wearable neurotechnology is enabling real-time neuromonitoring for Parkinson’s, MS, and post-stroke rehabilitation.

What Is Driving the Growth of IVD in Cardiology and Neurology?

The IVD market in cardiology and neurology is expanding due to several key growth drivers, including the rising prevalence of cardiovascular and neurodegenerative diseases, advancements in biomarker discovery, and the growing demand for non-invasive diagnostics. One of the most significant growth drivers is the global burden of CVD and stroke, which remain the leading causes of death worldwide. As healthcare systems focus on early detection, prevention, and personalized treatment approaches, the demand for high-sensitivity cardiac biomarkers and rapid stroke diagnostics is accelerating.

Another critical driver is the aging population, which is contributing to the increased incidence of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. With early-stage detection and intervention becoming a priority, IVD solutions based on blood-based biomarkers, genetic screening, and AI-driven neuroimaging analysis are gaining traction.

The increasing adoption of point-of-care (POC) testing and decentralized diagnostics is also fueling market growth. The shift from hospital-based laboratory testing to portable, rapid diagnostic solutions is enabling quicker decision-making, improved patient triage, and better management of acute cardiac and neurological conditions. As emergency medicine, primary care, and home-based diagnostics expand, IVD manufacturers are investing in compact, user-friendly, and highly sensitive POC testing platforms.

Regulatory and reimbursement support for IVD-driven precision medicine is another major factor influencing market growth. Governments and healthcare agencies are promoting biomarker-driven treatment strategies, genetic testing for hereditary conditions, and AI-integrated diagnostics to optimize patient outcomes and reduce healthcare costs. Additionally, the rising investments in digital health technologies and remote patient monitoring are driving innovation in AI-powered cardiac and neurological diagnostics.

SCOPE OF STUDY:

The report analyzes the IVD in Cardiology and Neurology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Instruments, Reagents & Consumables, Software & Services); Technology (Immunoassays, Molecular Diagnostics, Hematology, Others); End-Use (Hospitals, Clinical Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Agilent Technologies
• AliveCor
• Becton, Dickinson and Company (BD)
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Hologic Inc.
• LivaNova
• Medtronic
• Mindray Medical International Limited
• Ortho Clinical Diagnostics
• PerkinElmer Inc.
• QIAGEN N.V.
• Roche Diagnostics
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • IVD in Cardiology and Neurology - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Cardiovascular and Neurodegenerative Disorders Drives Demand for IVD Biomarkers
  • OEM Focus on Early Diagnosis and Risk Stratification Supports Adoption of Specialized IVD Panels
  • Growing Awareness of Stroke and Heart Attack Prevention Boosts Demand for Rapid Testing in Emergency Settings
  • Expansion of Point-of-Care Testing Capabilities Enhances IVD Use in Pre-Hospital and Critical Care Scenarios
  • Increased Investment in High-Sensitivity Troponin and NT-proBNP Assays Fuels Cardiac Test Innovation
  • OEM Innovation in Multi-Biomarker Panels Enables Comprehensive Cardiometabolic and Neuro Panel Testing
  • Integration of IVD With Imaging and EHR Systems Supports Clinical Decision-Making in Cardiology and Neurology
  • Rising Demand for Cost-Effective Stroke Risk Screening Tools Drives Expansion of Blood-Based Diagnostics
  • Expansion of Telecardiology and Teleneurology Services Fuels Need for Decentralized IVD Testing Platforms
  • Growth in Chronic Care Management Models Supports Regular Monitoring of Cardiac and Neurological Biomarkers
  • OEM Development of At-Home and Wearable IVD Devices Enhances Access to Long-Term Disease Monitoring
  • Aging Global Population and Increased Dementia Screening Drive Market for Alzheimers-Related Biomarkers
  • Rising Use of Genetic and Proteomic Testing in Neurology Drives Integration of IVD in Precision Medicine
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World IVD in Cardiology and Neurology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for IVD in Cardiology and Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Clinical Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• JAPAN
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• CHINA
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• EUROPE
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for IVD in Cardiology and Neurology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• FRANCE
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• GERMANY
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• INDIA
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for IVD in Cardiology and Neurology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for IVD in Cardiology and Neurology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
• AFRICA
  • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030

IV. COMPETITION